Adicet Bio Inc ACET

US Biotechnology

$6.83 ▲ +7.56% (+$0.48)

🎈 Low Float

Open $6.41

Prev Close $6.35

Day Range $6.37 – $7.06

52W Range $6.01 – $17.44

Market Cap $63.94M

Beta 1.61

EPS (TTM) $-13.02

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2018-01-26
Shares Out.	9,350,000
Website	adicetbio.com/ ↗
Phone	13026587581
Employees	102
Revenue	$0
Gross Profit	$0
Net Income	-$21.4M
Free Cash Flow	-$85.0M
Total Assets	$148.2M
Total Liabilities	$28.0M
Equity	$120.1M

About Adicet Bio Inc

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Adicet Bio Inc is a publicly traded company under the ticker symbol ACET on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.